Cylerus

Cylerus is a Seattle-based biotechnology company dedicated to advancing the field of in vivo cell engineering. The company's platform technology is designed to deliver genetic payloads directly to target cells within the body, eliminating the need for the costly and labor-intensive ex vivo manufacturing processes associated with traditional cell therapies. By leveraging specialized viral vector delivery systems, Cylerus aims to reprogram hematopoietic stem cells and immune cells to treat a variety of high-need indications, including genetic blood disorders and cancer. The company was founded by world-renowned experts from the Fred Hutchinson Cancer Center, building on decades of research in gene therapy and stem cell transplantation. Cylerus is currently in the pre-clinical stage, focusing on optimizing its delivery platform and expanding its pipeline of therapeutic candidates.